JP2024520713A5 - - Google Patents
Info
- Publication number
- JP2024520713A5 JP2024520713A5 JP2023574679A JP2023574679A JP2024520713A5 JP 2024520713 A5 JP2024520713 A5 JP 2024520713A5 JP 2023574679 A JP2023574679 A JP 2023574679A JP 2023574679 A JP2023574679 A JP 2023574679A JP 2024520713 A5 JP2024520713 A5 JP 2024520713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- inhibitor
- combination
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2107907.4 | 2021-06-02 | ||
| GBGB2107907.4A GB202107907D0 (en) | 2021-06-02 | 2021-06-02 | Combination therapies |
| PCT/GB2022/051400 WO2022254216A1 (en) | 2021-06-02 | 2022-06-01 | Combination therapies comprising a mettl3 inhibitor and a further anticancer agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520713A JP2024520713A (ja) | 2024-05-24 |
| JP2024520713A5 true JP2024520713A5 (https=) | 2025-06-06 |
Family
ID=76741389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574679A Pending JP2024520713A (ja) | 2021-06-02 | 2022-06-01 | Ｍｅｔｔｌ３阻害剤とさらなる抗がん剤を含む併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240277715A1 (https=) |
| EP (1) | EP4346814A1 (https=) |
| JP (1) | JP2024520713A (https=) |
| CN (1) | CN117460508A (https=) |
| AU (1) | AU2022285928A1 (https=) |
| CA (1) | CA3221771A1 (https=) |
| GB (1) | GB202107907D0 (https=) |
| WO (1) | WO2022254216A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117720533A (zh) * | 2022-09-16 | 2024-03-19 | 北京华益健康药物研究中心 | Mettl3抑制剂化合物及其药物组合物和应用 |
| AU2024244637A1 (en) | 2023-03-30 | 2025-10-16 | Aqemia | Novel mettl3 inhibitors and use thereof in therapy |
| WO2025121807A1 (ko) * | 2023-12-08 | 2025-06-12 | 인제대학교 산학협력단 | Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물 |
| KR20250088372A (ko) * | 2023-12-08 | 2025-06-17 | 인제대학교 산학협력단 | Btk 분해제와 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물 |
| WO2025237957A1 (en) * | 2024-05-14 | 2025-11-20 | Institut Curie | Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor |
| WO2026017846A1 (en) * | 2024-07-19 | 2026-01-22 | Epics Therapeutics | Piperidine derivatives as mettl3 inhibitors for the treatment of carcinomas |
| WO2026017844A1 (en) * | 2024-07-19 | 2026-01-22 | Epics Therapeutics | Combination therapies comprising a mettl3 inhibitor and a bcl2 inhibitor |
| CN118948887B (zh) * | 2024-07-26 | 2026-03-27 | 新乡市中心医院(新乡中原医院管理中心) | Mettl3抑制剂联合化疗药顺铂对宫颈癌的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| US20210164992A1 (en) * | 2018-07-23 | 2021-06-03 | New York University | Compositions and methods related to innate response to dna and regulation of interferon-beta |
| US20200081533A1 (en) | 2018-09-07 | 2020-03-12 | Microsoft Technology Licensing, Llc | Wearable device having regions of varying stiffnesses |
| WO2020201773A1 (en) * | 2019-04-05 | 2020-10-08 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
| US20230018989A1 (en) * | 2019-07-03 | 2023-01-19 | Children's Medical Center Corporation | Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis |
| CN115151540A (zh) * | 2019-12-02 | 2022-10-04 | 风暴治疗有限公司 | 作为mettl3抑制剂的多杂环化合物 |
-
2021
- 2021-06-02 GB GBGB2107907.4A patent/GB202107907D0/en not_active Ceased
-
2022
- 2022-06-01 WO PCT/GB2022/051400 patent/WO2022254216A1/en not_active Ceased
- 2022-06-01 AU AU2022285928A patent/AU2022285928A1/en active Pending
- 2022-06-01 US US18/565,336 patent/US20240277715A1/en active Pending
- 2022-06-01 EP EP22731289.9A patent/EP4346814A1/en active Pending
- 2022-06-01 CN CN202280040000.7A patent/CN117460508A/zh active Pending
- 2022-06-01 JP JP2023574679A patent/JP2024520713A/ja active Pending
- 2022-06-01 CA CA3221771A patent/CA3221771A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520713A5 (https=) | ||
| Dai et al. | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma | |
| Tsilimigras et al. | Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective | |
| Allard et al. | Targeting A2 adenosine receptors in cancer | |
| Allard et al. | Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs | |
| Cho et al. | Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside | |
| JP6356134B2 (ja) | 免疫応答の増強 | |
| Dong et al. | Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas | |
| Schneider et al. | Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response | |
| RU2729936C2 (ru) | Противораковое средство | |
| JP2022500419A5 (https=) | ||
| Zhang et al. | Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial | |
| JP2020525483A5 (https=) | ||
| Rousseau et al. | Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner | |
| CN110536702A (zh) | 使用hsp90抑制剂治疗癌症的方法 | |
| CN103442715A (zh) | 包括hdac抑制剂以及类固醇的药用组合物及其用途 | |
| Lu et al. | The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6 | |
| RU2019130325A (ru) | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ | |
| Müller et al. | 5-Azacytidine/5-Azacitidine | |
| KR20200128025A (ko) | 급성 골수성 백혈병 및 관련 병태의 치료 방법 | |
| Khan et al. | Antibody-directed therapies: toward a durable and tolerable treatment platform for CTCL | |
| FI3888647T3 (fi) | Ezh1/2-kaksoisestäjän sisältävä farmaseuttinen koostumus käytettäväksi yhdistelmälääkkeenä | |
| Zelent et al. | Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy | |
| Paolini | Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study | |
| TWI284643B (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |